D. E. Shaw reports 3.9% stake in Keros
Keros Therapeutics, Inc. received an updated ownership filing from D. E. Shaw entities and David E. Shaw.
Rhea-AI Filing Summary
Keros Therapeutics, Inc. received an updated ownership filing from D. E. Shaw entities and David E. Shaw. As of December 31, 2025, they report beneficial ownership of 756,156 shares of common stock, representing 3.9% of the outstanding shares.
The filing shows no sole voting or dispositive power; all authority over these shares is shared through various D. E. Shaw investment vehicles. David E. Shaw may be deemed a beneficial owner through his control of related entities but expressly disclaims beneficial ownership. The reporting persons also certify the shares are not held to change or influence control of Keros.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Keros Therapeutics (KROS) does D. E. Shaw report owning?
Is D. E. Shaw seeking to influence control of Keros Therapeutics (KROS)?
Which entities are included in the Keros Therapeutics (KROS) Schedule 13G/A by D. E. Shaw?
AI-generated analysis. How Rhea-AI works. Not financial advice.